Search Page

1

Cite

Share

A double-blind, controlled, crossover trial of amlodipine on iron overload status in transfusion dependent β-thalassemia patients.

Karami H, Khalilzadeh Arjmandi H, Salehifar E, Darvishi-Khezri H, Dabirian M, Kosaryan M, Aliasgharian A, Akbarzadeh R, Naeimayi Aali R, Nasirzadeh A. Karami H, et al. Among authors: kosaryan m. Int J Clin Pract. 2021 Aug;75(8):e14337. doi: 10.1111/ijcp.14337. Epub 2021 May 24. Int J Clin Pract. 2021. PMID: 33969592 Clinical Trial.

Cite

Share

2

Cite

Share

Can Use of Silymarin Improve Inflammatory Status in Patients with β-Thalassemia Major? A Crossover, Randomized Controlled Trial.

Darvishi-Khezri H, Kosaryan M, Karami H, Salehifar E, Mahdavi M, Alipour A, Aliasgharian A. Darvishi-Khezri H, et al. Among authors: kosaryan m. Complement Med Res. 2021;28(2):123-130. doi: 10.1159/000509829. Epub 2020 Sep 24. Complement Med Res. 2021. PMID: 32971524 Clinical Trial. English.

Cite

Share

3

Cite

Share

Non-invasive prenatal diagnosis of β-thalassemia by detection of the cell-free fetal DNA in maternal circulation: a systematic review and meta-analysis.

Zafari M, Kosaryan M, Gill P, Alipour A, Shiran M, Jalalli H, Banihashemi A, Fatahi F. Zafari M, et al. Among authors: kosaryan m. Ann Hematol. 2016 Aug;95(8):1341-50. doi: 10.1007/s00277-016-2620-3. Epub 2016 Mar 12. Ann Hematol. 2016. PMID: 26968552 Review.

Cite

Share

4

Cite

Share

Potential Effects of Silymarin and Its Flavonolignan Components in Patients with β-Thalassemia Major: A Comprehensive Review in 2015.

Darvishi Khezri H, Salehifar E, Kosaryan M, Aliasgharian A, Jalali H, Hadian Amree A. Darvishi Khezri H, et al. Among authors: kosaryan m. Adv Pharmacol Sci. 2016;2016:3046373. doi: 10.1155/2016/3046373. Epub 2016 Feb 21. Adv Pharmacol Sci. 2016. PMID: 26997953 Free PMC article. Review.

Cite

Share

5

Cite

Share

The effect and side effect of hydroxyurea therapy on patients with β-thalassemia: a systematic review to December 2012.

Kosaryan M, Zafari M, Alipur A, Hedayatizadeh-Omran A. Kosaryan M, et al. Hemoglobin. 2014;38(4):262-71. doi: 10.3109/03630269.2014.927770. Hemoglobin. 2014. PMID: 25023087 Review.

Cite

Share

6

Cite

Share

Moderate to severe liver siderosis and raised AST are independent risk factors for vitamin D insufficiency in β-thalassemia patients.

Darvishi-Khezri H, Karami H, Naderisorki M, Zahedi M, Razavi A, Kosaryan M, Aliasgharian A. Darvishi-Khezri H, et al. Among authors: kosaryan m. Sci Rep. 2020 Dec 3;10(1):21164. doi: 10.1038/s41598-020-78230-4. Sci Rep. 2020. PMID: 33273639 Free PMC article.

Cite

Share

7

Cite

Share

Treatment Status of Patients with B-Thalassemia Major in Northern Iran: Thalassemia Registry System.

Kosaryan M, Karami H, Darvishi-Khezri H, Akbarzadeh R, Aliasgharian A, Bromand K. Kosaryan M, et al. Iran J Public Health. 2019 Jul;48(7):1335-1345. Iran J Public Health. 2019. PMID: 31497556 Free PMC article.

Cite

Share

8

Cite

Share

Iron-chelating effect of silymarin in patients with β-thalassemia major: A crossover randomised control trial.

Darvishi-Khezri H, Salehifar E, Kosaryan M, Karami H, Mahdavi M, Alipour A, Aliasgharian A. Darvishi-Khezri H, et al. Among authors: kosaryan m. Phytother Res. 2018 Mar;32(3):496-503. doi: 10.1002/ptr.5995. Epub 2017 Dec 13. Phytother Res. 2018. PMID: 29235162 Clinical Trial.

Cite

Share

9

Cite

Share

Silymarin therapy and improvement of cardiac outcome in patients with β-thalassemia major.

Khezri HD, Kosaryan M, Salehifar E. Khezri HD, et al. Among authors: kosaryan m. J Res Pharm Pract. 2016 Jan-Mar;5(1):74-5. doi: 10.4103/2279-042X.176555. J Res Pharm Pract. 2016. PMID: 26985440 Free PMC article. No abstract available.

Cite

Share

10

Cite

Share

Prevalence of alloimmunisation in patients with beta thalassaemia major.

Kosaryan M, Mahdavi MR, Roshan P, Hojjati MT. Kosaryan M, et al. Blood Transfus. 2012 Jul;10(3):396-7. doi: 10.2450/2012.0072-11. Epub 2012 Feb 22. Blood Transfus. 2012. PMID: 22395351 Free PMC article. No abstract available.

Cite

Share